Combination treatment with pioglitazone and fenofibrate attenuates pioglitazone-mediated acceleration of bone loss in ovariectomized rats

Journal of Endocrinology

Volumn 212, Issue 2, 2012, Pages 179-186

  Samadfam, Rana ^a   Awori, Malaika ^a   Bénardeau, Agnes ^b   Bauss, Frieder ^c   Sebokova, Elena ^b   Wright, Matthew ^b   Smith, Susan Y ^a  

^a CHARLES RIVER LABORATORIES   (United States)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; CHOLESTEROL; FENOFIBRATE; INSULIN; OSTEOCALCIN; PIOGLITAZONE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY COMPOSITION; BODY FAT; BONE DENSITY; BONE MASS; BONE MINERAL; BONE TURNOVER; CHOLESTEROL BLOOD LEVEL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORTICAL BONE; DISEASE EXACERBATION; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMUR; FOLLOW UP; INSULIN BLOOD LEVEL; LUMBAR SPINE; METAPHYSIS; NONHUMAN; OSTEOLYSIS; OVARIECTOMY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; QUANTITATIVE ANALYSIS; RAT; TIBIA; TRABECULAR BONE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

ADIPOSITY; ANIMALS; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; COLLAGEN TYPE I; DRUG THERAPY, COMBINATION; FEMALE; FENOFIBRATE; HUMANS; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; OSTEOCALCIN; OSTEOPOROSIS, POSTMENOPAUSAL; OVARIECTOMY; PEPTIDES; PPAR ALPHA; PPAR GAMMA; RANDOM ALLOCATION; RATS; THIAZOLIDINEDIONES;

EID: 84863019643     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-11-0356     Document Type: Article

References (24)

1. Akune T, Ohba S, Kamekura S, Yamaguchi M, Chung UI, Kubota N, Terauchi Y, Harada Y, Azuma Y, Nakamura K et al. 2004 PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. Journal of Clinical Investigation 113 846-855.
2. Bays H, McElhattan J & Bryzinski BS 2007 A double-blind, randomised trial of tesaglitazar versus pioglitazone in patients with type 2 diabetes mellitus. Diabetes & Vascular Disease Research 4 181-193.
3. Boyce BF, Yao Z & Xing L 2009 Osteoclasts have multiple roles in bone in addition to bone resorption. Critical Reviews in Eukaryotic Gene Expression 19 171-180.
4. Chan BY, Gartland A, Wilson PJ, Buckley KA, Dillon JP, Fraser WD & Gallagher JA 2007 PPAR agonists modulate human osteoclast formation and activity in vitro. Bone 40 149-159.
5. Clarke B 2008 Normal bone anatomy and physiology. Clinical Journal of the American Society of Nephrology 3 (Suppl 3) S131-S139.
6. Eriksen EF 2010 Cellular mechanisms of bone remodeling. Reviews in Endocrine & Metabolic Disorders 11 219-227.
7. Glintborg D, Andersen M, Hagen C, Heickendorff L & Hermann AP 2008 Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial. Journal of Clinical Endocrinology and Metabolism 93 1696-1701.
8. Grey A, Bolland M, Gamble G, Wattie D, Horne A, Davidson J & Reid IR 2007 The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. Journal of Clinical Endocrinology and Metabolism 92 1305-1310.
9. Hasegawa T, Oizumi K, Yoshiko Y, Tanne K, Maeda N & Aubin JE 2008 The PPARgamma-selective ligand BRL-49653 differentially regulates the fate choices of rat calvaria versus rat bone marrow stromal cell populations. BMC Developmental Biology 8 71.
10. Henry RR, Lincoff AM, Mudaliar S, Rabbia M, Chognot C & Herz M 2009 Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. Lancet 374 126-135.
11. Jackson SM & Demer LL 2000 Peroxisome proliferator-activated receptor activators modulate the osteoblastic maturation of MC3T3-E1 preosteoblasts. FEBS Letters 471 119-124.
12. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B et al. 2006 Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. New England Journal of Medicine 355 2427-2443.
13. Karpe F & Ehrenborg EE 2009 PPARdelta in humans: genetic and pharmacological evidence for a significant metabolic function. Current Opinion in Lipidology 20 333-336.
14. Kendall DM, Rubin CJ, Mohideen P, Ledeine JM, Belder R, Gross J, Norwood P, O'Mahony M, Sall K, Sloan G et al. 2006 Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a double-blind, randomized, pioglitazonecomparative study. Diabetes Care 29 1016-1023.
15. Kumar S, Homan S, Samadfam R, Mansell P, Guldberg R, Smith SY & Fitzpatrick L 2009 ASBMR 31st Annual Meeting MO0001-MO0445. Journal of Bone and Mineral Research 24 S370-S496.
16. Lalloyer F & Staels B 2010 Fibrates, glitazones, and peroxisome proliferatoractivated receptors. Arteriosclerosis, Thrombosis, and Vascular Biology 30 894-899.
17. Manolagas SC, Kousteni S & Jilka RL 2002 Sex steroids and bone. Recent Progress in Hormone Research 57 385-409.
18. Schwartz AV 2006 Diabetes, TZDs, and bone: a review of the clinical evidence. PPAR Research 2006 24502.
19. Schwartz AV 2008 TZDs and bone: a review of the recent clinical evidence. PPAR Research 2008 297893.
20. Sierra ML, Beneton V, Boullay AB, Boyer T, Brewster AG, Donche F, Forest MC, Fouchet MH, Gellibert FJ, Grillot DA et al. 2007 Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potentHDLc raising agents. Journal of Medicinal Chemistry 50 685-695.
21. Sottile V, Seuwen K & Kneissel M 2004 Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARgamma agonist BRL49653 (rosiglitazone). Calcified Tissue International 75 329-337.
22. Spiegelman BM 1998 PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 47 507-514.
23. Stunes AK,Westbroek I, Gustafsson BI, Fossmark R,Waarsing JH, Eriksen EF, Petzold C, Reseland JE & Syversen U 2011 The peroxisome proliferatoractivated receptor (PPAR) alpha agonist fenofibrate maintains bone mass, while the PPAR gamma agonist pioglitazone exaggerates bone loss, in ovariectomized rats. BMC Endocrine Disorders 11 11.
24. Syversen U, Stunes AK, Gustafsson BI, Obrant KJ, Nordsletten L, Berge R, Thommesen L & Reseland JE 2009 Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)alpha agonist fenofibrate and the PPARgamma agonist pioglitazone. BMC Endocrine Disorders 9 10.